MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Legend Biotech Corp ADR

Suletud

SektorTervishoid

31.47 -7.2

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

31.34

Max

34.1

Põhinäitajad

By Trading Economics

Sissetulek

161M

41M

Müük

26M

187M

Aktsiakasum

0.14

Kasumimarginaal

21.719

Töötajad

2,600

EBITDA

162M

52M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+145.68% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

12. mai 2025

Turustatistika

By TradingEconomics

Turukapital

202M

6.7B

Eelmine avamishind

38.67

Eelmine sulgemishind

31.47

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Legend Biotech Corp ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. mai 2024, 11:36 UTC

Tulu

Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales

11. märts 2025, 11:09 UTC

Tulu

Legend Biotech 4Q Research and Development Expenses $104.4M >LEGN

11. märts 2025, 11:08 UTC

Tulu

Legend Biotech 4Q EPS 7c >LEGN

11. märts 2025, 11:00 UTC

Tulu

Legend Biotech 4Q Rev $186.5M >LEGN

12. nov 2024, 12:06 UTC

Tulu

Legend Biotech 3Q Loss/Shr 34c >LEGN

12. nov 2024, 12:05 UTC

Tulu

Legend Biotech 3Q Net Trade Sales ABout $286M >LEGN

12. nov 2024, 12:00 UTC

Tulu

Legend Biotech 3Q Rev $160.2M >LEGN

9. aug 2024, 11:02 UTC

Tulu

Legend Biotech 2Q License Rev Was $90.8M >LEGN

9. aug 2024, 11:01 UTC

Tulu

Legend Biotech 2Q Collaboration Rev $93.3M >LEGN

9. aug 2024, 11:01 UTC

Tulu

Legend Biotech 2Q Loss/Shr 5c >LEGN

9. aug 2024, 11:00 UTC

Tulu

Legend Biotech 2Q Rev $186.5M >LEGN

26. juuli 2024, 11:01 UTC

Tulu

Legend Biotech Expects 2H Adjusted Net Loss $94.7M

13. mai 2024, 11:02 UTC

Tulu

Legend Biotech 1Q Loss/Shr 16c >LEGN

13. mai 2024, 11:02 UTC

Tulu

Legend Biotech 1Q Research and Development Expenses $101.0M >LEGN

Võrdlus sarnastega

Hinnamuutus

Legend Biotech Corp ADR Prognoos

Hinnasiht

By TipRanks

145.68% tõus

12 kuu keskmine prognoos

Keskmine 83.36 USD  145.68%

Kõrge 95 USD

Madal 62 USD

Põhineb 15 Wall Streeti analüütiku instrumendi Legend Biotech Corp ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

15 ratings

13

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

N/A / 37.31Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.